Education
About Us
Working with TipRanks
Follow Us
PanGenomic Health, Inc. Class A (TSE:NARA)
:NARA
NARA Stock Chart & Stats
C$0.51
C$0.04(33.33%)
At close: 4:00 PM EST
C$0.51
C$0.04(33.33%)
Day’s Range― - ―
52-Week RangeC$0.16 - C$2.57
Previous CloseN/A
Volume0.00
Average Volume (3M)110.39K
Market Cap
C$4.49M
Enterprise ValueC$4.41M
Total Cash (Recent Filing)C$82.16K
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta0.98
Next Earnings
May 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding14,046,870
10 Day Avg. Volume77,322
30 Day Avg. Volume110,395
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)>-0.01
Price to Sales (P/S)0.00
P/FCF Ratio-0.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Reported DebtZero reported debt in the trailing twelve months reduces near-term refinancing pressure and lowers immediate interest obligations. This durable structural relief gives management more time to execute on commercialization or cost-reduction plans before needing new debt financing, improving short-term solvency.
Reduced Cash Burn In 2024A materially lower cash burn in 2024 versus prior years indicates improved operational efficiency or cost controls. Sustained lower burn extends the company’s runway, reduces near-term financing frequency, and if maintained, strengthens the firm’s ability to reach revenue inflection without constant external capital.
Active Financing And Distribution InitiativesRecent private placement and product/distribution initiatives show management is proactively securing capital and building commercial channels. These structural actions can materially improve liquidity and market access if executed, enabling longer-term development of revenue streams and partnership-driven growth.
Bears Say
No Recorded RevenueAbsence of recorded revenue across reported periods means the firm's business model remains unproven and product-market fit is unvalidated. Over a multi-month horizon this limits internal cash generation, increases dependence on financing, and heightens execution risk tied to achieving commercial traction.
Persistent Operating Cash BurnConsistent negative operating and free cash flow, including a TTM operating cash burn of ~1.7M, is a structural weakness. It erodes liquidity, forces repeated external funding, and raises dilution and execution risk unless the company achieves sustainable revenues or permanent cost reductions.
Negative Shareholders' EquityAccumulated deficits and negative equity limit financial flexibility and constrain strategic options. This structural capital shortfall can hinder partnerships, increase fundraising costs, and make future financing dilutive, posing a lasting constraint on the company’s ability to scale operations.
PanGenomic Health, Inc. Class A News
NARA FAQ
What was PanGenomic Health, Inc. Class A’s price range in the past 12 months?
PanGenomic Health, Inc. Class A lowest stock price was C$0.16 and its highest was C$2.57 in the past 12 months.
What is PanGenomic Health, Inc. Class A’s market cap?
PanGenomic Health, Inc. Class A’s market cap is C$4.49M.
When is PanGenomic Health, Inc. Class A’s upcoming earnings report date?
PanGenomic Health, Inc. Class A’s upcoming earnings report date is May 05, 2026 which is in 68 days.
How were PanGenomic Health, Inc. Class A’s earnings last quarter?
PanGenomic Health, Inc. Class A released its earnings results on Dec 01, 2025. The company reported -C$0.113 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.113.
Is PanGenomic Health, Inc. Class A overvalued?
According to Wall Street analysts PanGenomic Health, Inc. Class A’s price is currently Overvalued.
Does PanGenomic Health, Inc. Class A pay dividends?
PanGenomic Health, Inc. Class A does not currently pay dividends.
What is PanGenomic Health, Inc. Class A’s EPS estimate?
PanGenomic Health, Inc. Class A’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PanGenomic Health, Inc. Class A have?
PanGenomic Health, Inc. Class A has 14,046,870 shares outstanding.
What happened to PanGenomic Health, Inc. Class A’s price movement after its last earnings report?
PanGenomic Health, Inc. Class A reported an EPS of -C$0.113 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 35.135%.
Which hedge fund is a major shareholder of PanGenomic Health, Inc. Class A?
Currently, no hedge funds are holding shares in TSE:NARA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PanGenomic Health, Inc. Class A
Pangenomic Health Inc., a precision health company, develops a self-care digital platform to deliver personalized and evidence-based information about natural treatments to support mental health. It develops the Nara App, a mobile app that provides consumers with a knowledge base tailored to an individual's unique user profile; and the PlantGx Platform, a digital therapeutics clinic platform that provides health practitioners with access to user health data enabled from the Nara App by the patient and to receive patient referrals. The company was formerly known as Zetta Capital Corp. and changed its name to PanGenomic Health Inc. in December 2021. Pangenomic Health Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.
Technical Analysis
Diagnos
―
nDatalyze Corp
―
Rocket Doctor AI
―
UniDoc Health Corp
―
DiagnaMed Holdings Corp.
―
Options Prices
Currently, No data available
---